This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I love a good regulatory debate. Biohaven Pharmaceuticals has given us a new one to chew over.
On Monday, the company said it planned to submit a marketing application to the Food and Drug Administration before the end of the year, seeking approval for an experimental drug called troriluzole to delay progression of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in